SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Mountain Crest Acquisition Corp. II – MCAD

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. NEW YORK, April 24, 2021 /PRNewswire/ --Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Mountain Crest Acquisition Corp. II ("MCAD" or the "Company") (MCAD) relating to its proposed merger with Better Therapeutics. Under the terms of the agreement, MCAD will acquire Better through a reverse merger, with Better emerging as a publicly traded company.The investigation focuses on whether Mountain Crest Acquisition Corp. II and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.Click here for more information: https://www.monteverdelaw.com/case/mountain-crest-acquisition-corp-ii. It is free and there is no cost or obligation to you. About Monteverde & Associates PCWe are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.If you own common stock in Mountain Crest Acquisition Corp. II and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.Contact:Juan E. Monteverde, Esq.MONTEVERDE & ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4405New York, NY 10118United States of Americajmonteverde@monteverdelaw.comTel: (212) 971-1341Attorney Advertising. (C) 2021 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter. View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-mountain-crest-acquisition-corp-ii--mcad-301276253.htmlSOURCE Monteverde & Associates PC To keep reading about SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Mountain Crest Acquisition Corp. II – MCAD, Click on the link. Seoul, Korea
http://dlvr.it/RyKnz7

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint